UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model

Pigment Cell and Melanoma Research

Volumn 30, Issue 4, 2017, Pages 428-435

  Wang, Jake ^a   Perry, Curtis J ^a   Meeth, Katrina ^a   Thakral, Durga ^a   Damsky, William ^a   Micevic, Goran ^a   Kaech, Susan ^a   Blenman, Kim ^a   Bosenberg, Marcus ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Braf; immunotherapy; melanoma; mouse models; UV radiation

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GREEN FLUORESCENT PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CLONE; CONTROLLED STUDY; DNA CONTENT; FLOW CYTOMETRY; IMMUNOGENICITY; IMMUNOSURVEILLANCE; MELANOMA; MELANOMA CELL LINE; MOUSE; NONHUMAN; PHENOTYPE; POINT MUTATION; RADIATION EXPOSURE; SANGER SEQUENCING; SOMATIC MUTATION; T LYMPHOCYTE; TUMOR GROWTH; ULTRAVIOLET RADIATION; WHOLE EXOME SEQUENCING; ANIMAL; APOPTOSIS; C57BL MOUSE; DISEASE MODEL; GENETICS; METABOLISM; MITOSIS; MUTATION; PATHOLOGY; RADIATION RESPONSE;

ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; GREEN FLUORESCENT PROTEINS; MELANOMA; MICE, INBRED C57BL; MITOSIS; MUTATION; T-LYMPHOCYTES; ULTRAVIOLET RAYS; WHOLE EXOME SEQUENCING;

EID: 85020303683     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12591     Document Type: Article

References (24)

1. Becker, J. C., Houben, R., Schrama, D., Voigt, H., Ugurel, S., & Reisfeld, R. A. (2010). Mouse models for melanoma: A personal perspective. Experimental Dermatology, 19, 157–164.
2. Cancer Genome Atlas, N (2015). Genomic classification of cutaneous melanoma. Cell, 161, 1681–1696.
3. Castle, J. C., Kreiter, S., Diekmann, J., Lower, M., Van De Roemer, N., De Graaf, J., … Sahin, U. (2012). Exploiting the mutanome for tumor vaccination. Cancer Research, 72, 1081–1091.
4. Day, C. P., Merlino, G., & Van Dyke, T. (2015). Preclinical mouse cancer models: A maze of opportunities and challenges. Cell, 163, 39–53.
5. Ho, P. C., Bihuniak, J. D., Macintyre, A. N., Staron, M., Liu, X., Amezquita, R., … Kaech, S. M. (2015). Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell, 162, 1217–1228.
6. Homet Moreno, B., Zaretsky, J. M., Garcia-Diaz, A., Tsoi, J., Parisi, G., Robert, L., … Ribas, A. (2016). Response to programmed cell death-1 blockade in a murine melanoma syngeneic model requires costimulation, CD4, and CD8 T cells. Cancer Immunology Research, 4, 845–857.
7. Ji, R. R., Chasalow, S. D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J., … Shahabi, V. (2012). An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunology, Immunotherapy, 61, 1019–1031.
8. Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., … Diaz, L. A. Jr. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. The New England Journal of Medicine, 372, 2509–2520.
9. Mak, I. W., Evaniew, N., & Ghert, M. (2014). Lost in translation: Animal models and clinical trials in cancer treatment. American Journal of Translational Research, 6, 114–118.
10. Martincorena, I., Roshan, A., Gerstung, M., Ellis, P., Van Loo, P., Mclaren, S., … Campbell, P. J. (2015). Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science, 348, 880–886.
11. Meeth, K., Wang, J. X., Micevic, G., Damsky, W., & Bosenberg, M. W. (2016). The YUMM lines: A series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment Cell & Melanoma Research, 29, 590–597.
12. Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 12, 252–264.
13. Scortegagna, M., Lau, E., Zhang, T., Feng, Y., Sereduk, C., Yin, H., … Ronai, Z. A. (2015). PDK1 and SGK3 contribute to the growth of BRAF-mutant melanomas and are potential therapeutic targets. Cancer Research, 75, 1399–1412.
14. Shain, A. H., Yeh, I., Kovalyshyn, I., Sriharan, A., Talevich, E., Gagnon, A., … Bastian, B. C. (2015). The genetic evolution of melanoma from precursor lesions. The New England Journal of Medicine, 373, 1926–1936.
15. Sharma, P., & Allison, J. P. (2015). The future of immune checkpoint therapy. Science, 348, 56–61.
16. Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., … Chan, T. A. (2014). Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England Journal of Medicine, 371, 2189–2199.
17. Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., … Sakaguchi, S. (2000). Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. Journal of Experimental Medicine, 192, 303–310.
18. Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015). Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell, 27, 450–461.
19. Utzschneider, D. T., Alfei, F., Roelli, P., Barras, D., Chennupati, V., Darbre, S., … Zehn, D. (2016). High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival. Journal of Experimental Medicine, 213, 1819–1834.
20. Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., … Garraway, L. A. (2015). Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science, 350, 207–211.
21. Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A. Jr, & Kinzler, K. W. (2013). Cancer genome landscapes. Science, 339, 1546–1558.
22. Ward, J. P., Gubin, M. M., & Schreiber, R. D. (2016). The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer. Advances in Immunology, 130, 25–74.
23. Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., … Sakaguchi, S. (2008). CTLA-4 control over Foxp3+ regulatory T cell function. Science, 322, 271–275.
24. Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., … Sznol, M. (2013). Nivolumab plus ipilimumab in advanced melanoma. The New England Journal of Medicine, 369, 122–133.